Piflufolastat is named as an intervention in 2 current clinical trials in our USA, UK and China registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Novartis Pharmaceuticals (1). The most-studied condition is Oligometastatic Prostate Cancer (OMPC). The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
NCT07569926 · ClinicalTrials.gov ↗ · Prostate Cancer
|
Phase 4 | Recruiting | Blue Earth Diagnostics | USA |
|
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414 · Oligometastatic Prostate Cancer (OMPC)
|
Phase 3 | Recruiting | Novartis Pharmaceuticals | UK, USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Piflufolastat. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment
2026-525181-22-00 · CTIS ↗ · Diagnosis
|
Phase 4 | Authorised | Centre Hospitalier Universitaire De Toulouse | France |
|
LAMP-COVID: Locating Amyloid-containing Microclots with total-body PET in post-COVID syndrome
2025-522348-42-00 · CTIS ↗ · Virus Diseases
|
Phase 1 | Ongoing | Amsterdam UMC Stichting | Netherlands |
|
(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson’s Disease or Multiple System Atrophy
2025-522653-19-00 · CTIS ↗ · Nervous System Diseases
|
Phase 4 | Authorised | Askbio Inc | Poland |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
| Blue Earth Diagnostics | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in China | 1 | 1 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our USA, UK and China registers name Piflufolastat (also registered as 18F) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 1 with sites in UK and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novartis Pharmaceuticals (1) and Blue Earth Diagnostics (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Piflufolastat works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Piflufolastat works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Piflufolastat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.